Sort
64,565 grants matching “drug discovery”
Development Of Drugs Acting At Adenosine Receptors
$724,885Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
Molecular Genetic Analysis of Mycobacterium tuberculosis
$724,867William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2014 · AI
Airway epithelial cytoglobin regulates nitric oxide synthase and development of primary ciliary dyskinesia and situs inversus
$724,867Mark Thomas Gladwin · University Of Maryland Baltimore · R01 · FY2024 · HL
National cooperative drug discovery groups for treatment of mood disorder
$724,863Scripps Research Institute · U01 · FY2005 · MH
GABA B compounds for depression and smoking cessation
$724,863Scripps Research Institute · U01 · FY2005 · MH
Defining an Obesity QTL on Chromosome 3q
$724,830Xiaofeng Zhu · Loyola University Chicago · R01 · FY2006 · HL
Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and Biology
$724,631Laura M Bohn · Scripps Florida · R01 · FY2011 · DA
Optopatch:high-throughput all-optical electrophysiology
$724,571Yang Lu · Q-State Biosciences, Inc. · R44 · FY2020 · MH
Integrated, Individualized, and Intelligent Prescribing (I3P) Clinical Trial Network
$724,563Josh F. Peterson · Vanderbilt University Medical Center · U01 · FY2023 · HG
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen
$724,489George Louis Drusano · University Of Florida · R01 · FY2014 · AI
Hit-to-lead optimization for heart failure drug discovery
$724,316Lennane Michel Espinoza-Fonseca · University Of Michigan At Ann Arbor · R01 · FY2019 · HL
Hit-to-lead optimization for heart failure drug discovery
$724,316Lennane Michel Espinoza-Fonseca · University Of Michigan At Ann Arbor · R01 · FY2020 · HL
Hit-to-lead optimization for heart failure drug discovery
$724,316Lennane Michel Espinoza-Fonseca · University Of Michigan At Ann Arbor · R01 · FY2021 · HL
Hit-to-lead optimization for heart failure drug discovery
$724,316Lennane Michel Espinoza-Fonseca · University Of Michigan At Ann Arbor · R01 · FY2022 · HL
Structural Basis of Protease-Activated Receptor Function
$724,313Shaun R. Coughlin · University Of California, San Francisco · R01 · FY2015 · HL
CWRU/UHICC Phase I Trials of Anticancer Agents
$724,297Case Western Reserve University · U01 · FY2004 · CA
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells
$724,286Yadong Huang · J. David Gladstone Institutes · R01 · FY2023 · AG
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells
$724,286Yadong Huang · J. David Gladstone Institutes · R01 · FY2024 · AG
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells
$724,286Yadong Huang · J. David Gladstone Institutes · R01 · FY2022 · AG
Study the Protective Roles of ApoE2 in Alzheimer's Disease Using Reprogrammed Isogenic Cells
$724,286Yadong Huang · J. David Gladstone Institutes · R01 · FY2021 · AG
Tools for drug efficacy studies in perfused tissue models
$724,224Jelena Vukasinovic · Lena Biosciences, Inc. · R44 · FY2018 · TR
Novel lead compound advancement for mitigating halogen-induced mortality and morbidity.
$724,165Shama Ahmad · University Of Alabama At Birmingham · U01 · FY2024 · ES
MECHANISMS UNDERLYING THE AGE-RELATED ATHEROPROTECTIVE EFFECTS OF HORMONE THERAPY
$724,027Howard N Hodis · University Of Southern California · R01 · FY2021 · AG
MECHANISMS UNDERLYING THE AGE-RELATED ATHEROPROTECTIVE EFFECTS OF HORMONE THERAPY
$724,027Howard N Hodis · University Of Southern California · R01 · FY2018 · AG
MECHANISMS UNDERLYING THE AGE-RELATED ATHEROPROTECTIVE EFFECTS OF HORMONE THERAPY
$724,027Howard N Hodis · University Of Southern California · R01 · FY2022 · AG